Arvinas Announces the Initiation of Patient Dosing in a First-in-Human Phase 1 Study of ARV-471, an Estrogen Receptor-Targeting PROTAC® Protein Degrader

August 27, 2019

We're not around right now. But you can send us an email and we'll get back to you, asap.

Start typing and press Enter to search